Advertisement

Mechanisms of Thrombogenesis

  • Anna Falanga
  • Laura Russo
  • Marina Marchetti
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Thrombosis is a leading cause of morbidity and mortality in patients with polycythemia vera (PV) and essential thrombocythemia (ET). A number of mechanisms have been proposed to play a role in the pathogenesis of the acquired thrombophilic state in these diseases, including red blood cell, platelet, and leukocyte abnormalities. Published data demonstrate that neutrophil activation occurs in ET and PV patients in parallel with the appearance of laboratory signs of hemostatic system activation, suggesting an involvement of these cells in the pathogenesis of the thrombotic predisposition of these subjects. Recently, an increase in plasma procoagulant microparticles and the occurrence of an acquired activated protein C resistance have been identified as other two possible mechanisms of systemic hypercoagulability. The acquired point mutation in the pseudokinase domain of Janus kinase 2 (JAK2V617F) in these disorders is under evaluation as a risk factor for thrombosis. JAK2V617F is variably associated with thrombosis and, more consistently, with elevations in blood cell counts. A clear link appears to exist between leukocytosis, JAK2V617F, and the hemostatic system abnormalities underlying the activation of blood coagulation in patients with Bcl-negative myeloproliferative neoplasms.

Keywords

Polycythemia Vera Essential Thrombocythemia JAK2V617F Mutation Polycythemia Vera Patient Acute Chest Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adams BD et al (2010) Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am 24:585–602PubMedCrossRefGoogle Scholar
  2. Afshar-Kharghan V, Thiagarajan P (2006) Leukocyte adhesion and thrombosis. Curr Opin Hematol 13:34–39PubMedCrossRefGoogle Scholar
  3. Alvarez-Larran A et al (2004) Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 124:329–335PubMedCrossRefGoogle Scholar
  4. Alvarez-Larran A et al (2008) Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 87:269–276PubMedCrossRefGoogle Scholar
  5. Arellano-Rodrigo E et al (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169–175PubMedGoogle Scholar
  6. Arellano-Rodrigo E et al (2009) Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 84:102–108PubMedCrossRefGoogle Scholar
  7. Baxter EJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedGoogle Scholar
  8. Bucalossi A et al (1996) Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 52:14–20PubMedCrossRefGoogle Scholar
  9. Buss DH et al (1985) The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 20:365–372PubMedCrossRefGoogle Scholar
  10. Carobbio A et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310–2313PubMedCrossRefGoogle Scholar
  11. Carobbio A et al (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 26:2732–2736PubMedCrossRefGoogle Scholar
  12. Cervantes F et al (2006) Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 20:55–60PubMedCrossRefGoogle Scholar
  13. Cortelazzo S et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132–1136PubMedCrossRefGoogle Scholar
  14. De Stefano V et al (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85:97–100PubMedGoogle Scholar
  15. Duchemin J et al (2010) Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126:238–242PubMedCrossRefGoogle Scholar
  16. Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275–290PubMedCrossRefGoogle Scholar
  17. Falanga A et al (1994) Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia. Semin Thromb Hemost 20:324–327PubMedCrossRefGoogle Scholar
  18. Falanga A et al (1999) Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 93:2506–2514PubMedGoogle Scholar
  19. Falanga A et al (2000) Polymorphonuclear leukocyte ­activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96:4261–4266PubMedGoogle Scholar
  20. Falanga A et al (2005a) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 42:239–247PubMedCrossRefGoogle Scholar
  21. Falanga A et al (2005b) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 33:523–530PubMedCrossRefGoogle Scholar
  22. Falanga A et al (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35:702–711PubMedCrossRefGoogle Scholar
  23. Finazzi G, Barbui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494–1502PubMedCrossRefGoogle Scholar
  24. Gangat N et al (2009) Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 115:5740–5745PubMedCrossRefGoogle Scholar
  25. Harrison CN (2005) Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 1:409–415CrossRefGoogle Scholar
  26. Harrison CN et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45PubMedCrossRefGoogle Scholar
  27. Huang PY, Hellums JD (1993) Aggregation and disaggregation kinetics of human blood platelets: Part I. Development and validation of a population balance method. Biophys J 65:334–343PubMedCrossRefGoogle Scholar
  28. Jensen MK et al (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 110:116–124PubMedCrossRefGoogle Scholar
  29. Jensen MK et al (2001) Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 66:143–151PubMedCrossRefGoogle Scholar
  30. Kralovics R et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790PubMedCrossRefGoogle Scholar
  31. Kubota Y et al (2004) Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 18:1127–1137PubMedCrossRefGoogle Scholar
  32. Kwaan HC, Wang J (2003) Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 29:451–458PubMedCrossRefGoogle Scholar
  33. Landolfi R et al (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965–1971PubMedGoogle Scholar
  34. Landolfi R et al (1995) Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Hematol 20:203–222PubMedCrossRefGoogle Scholar
  35. Landolfi R et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124PubMedCrossRefGoogle Scholar
  36. Landolfi R et al (2006) Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 19:617–633PubMedCrossRefGoogle Scholar
  37. Landolfi R et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446–2452PubMedCrossRefGoogle Scholar
  38. Levine RL et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397PubMedCrossRefGoogle Scholar
  39. Lussana F et al (2009) Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 124:409–417PubMedCrossRefGoogle Scholar
  40. Marchetti M, Falanga A (2008) Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb 36:148–159PubMedCrossRefGoogle Scholar
  41. Marchetti M et al (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112:4061–4068PubMedCrossRefGoogle Scholar
  42. Michiels JJ et al (2006) Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 32:174–207PubMedCrossRefGoogle Scholar
  43. Palandri F et al (2011) Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 90:933–938PubMedCrossRefGoogle Scholar
  44. Panova-Noeva M et al (2011) Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 86:337–342PubMedCrossRefGoogle Scholar
  45. Pearson MJ, Lipowsky HH (2000) Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery. Am J Physiol Heart Circ Physiol 279:H1460–H1471PubMedGoogle Scholar
  46. Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219–1222PubMedCrossRefGoogle Scholar
  47. Posan E et al (1998) Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res 90:51–56PubMedCrossRefGoogle Scholar
  48. Rafail S et al (2008) Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNFalpha involvement. Thromb Res 122:366–375PubMedCrossRefGoogle Scholar
  49. Robertson B et al (2007) Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 5:1679–1685PubMedCrossRefGoogle Scholar
  50. Schafer AI (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1–12PubMedGoogle Scholar
  51. Schafer AI (2004) Thrombocytosis. N Engl J Med 350:1211–1219PubMedCrossRefGoogle Scholar
  52. Stuart MJ, Nagel RL (2004) Sickle-cell disease. Lancet 364:1343–1360PubMedCrossRefGoogle Scholar
  53. Tefferi A (2011) Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:292–301PubMedCrossRefGoogle Scholar
  54. Thomas DJ et al (1977) Effect of haematocrit on cerebral blood-flow in man. Lancet 2:941–943PubMedCrossRefGoogle Scholar
  55. Trappenburg MC et al (2009) Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 94:911–918PubMedCrossRefGoogle Scholar
  56. Turitto VT, Weiss HJ (1980) Red blood cells: their dual role in thrombus formation. Science 207:541–543PubMedCrossRefGoogle Scholar
  57. Turitto VT, Weiss HJ (1983) Platelet and red cell involvement in mural thrombogenesis. Ann N Y Acad Sci 416:363–376PubMedCrossRefGoogle Scholar
  58. Villmow T et al (2002) Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 108:139–145PubMedCrossRefGoogle Scholar
  59. Wieczorek I et al (1995) Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. Am J Hematol 49:277–281PubMedCrossRefGoogle Scholar
  60. Yedgar S et al (2002) The red blood cell in vascular occlusion. Pathophysiol Haemost Thromb 32:263–268PubMedCrossRefGoogle Scholar
  61. Zhao R et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788–22792PubMedCrossRefGoogle Scholar
  62. Zwicker JI et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830–6840PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Division of Immunohematology and Transfusion MedicineOspedali Riuniti di BergamoBergamoItaly

Personalised recommendations